How Long Does a UC Flare Last? What Decides It

Here is the honest answer, and it is not the one most pages give you: nobody has measured how long a ulcerative colitis flare lasts. There is no published average, no median, no range from a proper dataset. What exists instead are treatment timelines and long-term cohort studies, and read together they point at a different answer to the one you were probably looking for.

A UC flare lasts until a treatment that works for you takes hold. That is not a dodge. It is what the numbers keep saying. Mild flares caught early and treated well often settle within days to a few weeks. Flares where the first drug does not work, and then the second does not work, run for months, because each attempt takes six to ten weeks to judge fairly. And a real minority of people spend years with disease that never fully quietens, which is why the forum threads look so alarming when you are three weeks into your first flare and searching for reassurance.

This article walks through what is actually known: what the trials clock, what the natural history cohorts found, what makes a flare drag, and what you can usefully do while you wait.

Why there is no published average, and how to spot a page that invented one

Every large ulcerative colitis trial in the last two decades has the same shape. Everyone starts with active disease. Everyone gets the drug or placebo. Then a single fixed date arrives and the researchers count who is in remission. The trial never records the date any individual's symptoms stopped, so the data to compute an average duration was never collected.

You can see this in the trials themselves. Infliximab's ACT 1 and ACT 2 counted clinical response at week 8 (Rutgeerts 2005). Vedolizumab's GEMINI 1 counted response at week 6 (Feagan 2013). Tofacitinib's OCTAVE Induction trials counted remission at week 8 (Sandborn 2017). Ustekinumab's UNIFI counted remission at week 8 (Sands 2019). Ozanimod's True North used a 10-week induction period (Sandborn 2021). Upadacitinib's two induction studies ran eight weeks (Danese 2022).

Those weeks are design decisions, chosen because they are long enough for the drug to work and short enough to keep people on placebo ethically. They are not measurements of how long colitis takes to calm down.

So when a health page tells you "a UC flare typically lasts two to six weeks", ask yourself where that came from. It did not come from a study, because no such study exists. What it most likely came from is the induction window of the commonest first-line treatment, reworded into a prognosis. That is a different claim, and a much weaker one.

The real numbers: what happened by week 8 in the big trials

If you want something concrete, this is the closest thing. All of these are moderate-to-severe UC in people whose previous treatments had not worked, which is a sicker group than the average person reading this.

Two things jump out. First, "response" and "remission" are wildly different bars, which is why 69% and 18.5% can both be true of effective drugs. Response means your Mayo score dropped meaningfully and your bleeding improved. Remission means you are essentially symptom free with a near-normal lining. A page that mixes the two is misleading you.

Second, and this is the part that matters for duration: even the best numbers mean a substantial share of people reach week 8 without the result they needed. For them, the flare does not end at week 8. It continues into the next attempt.

The fastest a flare can turn: what the first few days look like

Some treatments move quickly. A post hoc analysis of the two tofacitinib induction trials looked at daily diary entries from the first 15 days. By day three, 28.8% of people on tofacitinib had improved their stool frequency subscore by at least one point, against 17.9% on placebo, and 32.0% versus 20.1% had improved their rectal bleeding subscore (Hanauer 2019). That same day-three checkpoint is where the admission decision gets made, which our guide to when to go to the hospital for a UC flare sets out in full.

Read that carefully, because it is easy to oversell. This was a post hoc analysis, meaning the question was asked after the data existed rather than planned in advance. The mean changes by day three were small: a reduction of 0.27 of a point in stool frequency subscore versus 0.11. And nearly one in five people on placebo also improved by a point in three days, which tells you how noisy a single day of symptoms is. The finding is real and the drug does act fast. It is not a promise that you will feel different by Thursday.

Steroids are the other fast option. In the Olmsted County population study of everyone's first course of systemic steroids, the 30-day outcome for the 63 people with UC was complete remission in 54%, partial remission in 30% and no response in 16% (Faubion 2001). That is a good short-term hit rate, and it is why steroids remain a standard way to break a flare. What happens next is the part nobody mentions, and it is the whole story of the long flare.

Why "until a drug works" is the most accurate answer available

Go back to that same Olmsted County cohort and look one year out rather than 30 days. Of the people with UC who took a first course of steroids, at one year 49% had a prolonged response, 22% were steroid dependent, and 29% had had an operation (Faubion 2001). Just under half were steroid free without surgery.

That means for roughly half of people, the first serious attempt at ending the flare did not end it. And each subsequent attempt has a clock attached: six weeks for one drug, eight for another, ten for another. Two failed treatments is four to five months before you even reach a third. Nothing went wrong. That is the arithmetic.

This is exactly what people in UC communities land on when they answer the question themselves. In an r/UlcerativeColitis survey thread asking how long flares last, several of the most direct answers were variations on "until I find a drug that stops it" and "indefinitely, until I get on a medication that helps" (r/UlcerativeColitis thread). People who have lived with it have worked out the mechanism without the papers.

How some people flare for a year: the actual proportion

The single most useful number here comes from a Danish cohort of 1,161 people with UC followed from diagnosis for up to 25 years. Across the whole follow-up, about 50% of patients were in clinical remission at any given time, and 90% had a relapsing course over 25 years. But the detail that answers the year-long question sits in a narrower window. During years three to seven after diagnosis, 25% of patients were in remission throughout, 18% had disease activity every single year, and 57% had intermittent relapses (Langholz 1994).

So roughly one in five people, in that window, had active disease every year. That is who is writing the posts that frightened you.

An r/IBD thread titled "How do some people flare for a year?!" collected exactly those replies: multi-year flares, cycling through biologics, one person describing a decade before they had any frame of reference for what remission felt like (r/IBD thread). Treat it as lived experience, not data. Forums select hard for the people having the worst time, and one commenter in the survey thread said so themselves, noting that those who post on Reddit usually have it the worst. The Danish cohort is the unbiased version of the same picture, and it says a long course is a real minority experience rather than the norm.

The same cohort also found that relapses were largely unpredictable, with one exception: disease activity in the preceding years predicted activity in the following year with 70 to 80% probability (Langholz 1994). If your last two years have been rough, that is the strongest single signal about the year ahead, and it is a reason to press for a treatment review rather than to despair.

A smaller study looked at the same question prospectively. Seventy-four people with clinically and endoscopically inactive UC were followed for a year, and 27 relapsed. On multivariate analysis the independent predictors of a shorter time to relapse were younger age (hazard ratio 0.4 per decade), a greater number of prior relapses in women (hazard ratio 1.6 per prior relapse), and basal plasmacytosis on rectal biopsy, a microscopic finding you cannot feel, which carried a hazard ratio of 4.5 (Bitton 2001). Seventy-four people is a small cohort and the sex-specific finding was not replicated in the larger cohorts, so hold it loosely. The pattern it reinforces is the one that runs through this whole article: the things that predict how your disease behaves next are often invisible to you.

Does the extent of your colitis change how long flares last?

This is the question the survey thread was explicitly built around, asking everyone to state whether they had proctitis, left-sided disease or pancolitis. The answers did not sort cleanly, and the research explains why.

Extent predicts risk, not duration. In the Norwegian IBSEN inception cohort followed for 20 years, extensive colitis at diagnosis was independently associated with a higher risk of colectomy than proctitis, with a hazard ratio of 2.8 (95% CI 1.3 to 6.1). The overall 20-year cumulative colectomy risk was 13.0% (Monstad 2021). That is a statement about surgery over two decades, not about how many weeks your current flare will run.

Proctitis is also not a fixed diagnosis. In an Italian multicentre study of 341 people with an initial diagnosis of ulcerative proctitis, 273 entered long-term follow-up averaging 52 months, and proximal extension of the disease occurred in 27.1% of them. The cumulative extension rate was 20% at five years and 54% at ten years, with extension beyond the splenic flexure in 4% and 10% respectively. Risk of extension was higher in non-smokers, in people with more than three relapses a year, and in people who needed systemic steroids or immunosuppressive treatment (Meucci 2000).

So a proctitis flare that drags on is worth reporting rather than tolerating, partly because refractory disease was an independent predictor of extension in that study.

One practical point on extent and duration that does have decent evidence behind it: if your disease is distal and you are on oral treatment only, you may be undertreated. A meta-analysis of 12 randomised trials found that combined oral plus topical 5-ASA beat oral alone for inducing remission in active UC, with a relative risk of no remission of 0.65 (95% CI 0.47 to 0.91) and a number needed to treat of 5. For preventing relapse in quiescent UC, intermittent topical beat oral alone with an NNT of 4 (Ford 2012). Twelve trials is a small evidence base, and the comparison of topical versus oral for inducing remission was not statistically significant on its own. But if nobody has ever discussed suppositories or enemas with you and your disease is left-sided or rectal, that is a fair question to raise.

Acute severe colitis: the one flare with a clock on it

Most of this article is about flares measured in weeks. There is one kind that is measured in days, and it is the one where guessing at durations is actively dangerous.

The definition has barely changed since 1955. Truelove and Witts classified an attack as severe when someone had six or more bloody stools a day together with systemic upset: fever, a fast pulse, anaemia or a raised ESR. Under four stools a day with no systemic features was mild (Truelove 1955). Those thresholds still anchor current guidance, and the 2025 ACG guideline update for ulcerative colitis in adults still frames severity and escalation around them (Rubin 2025). The European Crohn's and Colitis Organisation's therapeutics guideline for ulcerative colitis takes the same approach to medical treatment of an acute severe attack (Raine 2022), as do the 2025 British Society of Gastroenterology guidelines, which state they were produced without external commercial funding and with contributors supported through their public-sector and NHS roles (Moran 2025).

Once someone is admitted with acute severe colitis and started on intravenous steroids, the assessment happens on day three, not week eight. In the Oxford series of 51 consecutive episodes, stool frequency and CRP over the first five days separated the outcomes. It could be predicted on day three that 85% of patients with more than eight stools that day, or three to eight stools together with a CRP above 45 mg/L, would need a colectomy on that admission (Travis 1996). That index descends directly from the intensive intravenous regimen Truelove and Jewell described in 1974, which was deliberately built around a short, defined course rather than an open-ended one (Truelove 1974).

If steroids fail, rescue therapy is also judged fast. In a European trial of 115 people with steroid-refractory acute severe UC, response was assessed at day seven as part of the primary endpoint. The trial was a null result: treatment failure occurred in 60% on ciclosporin and 54% on infliximab, an absolute risk difference of 6% with a confidence interval spanning minus 7 to plus 19, and a p value of 0.52. Neither drug was better than the other (Laharie 2012). Worth noting: that trial was funded by a patient association, a national gastroenterology society and an academic IBD organisation, not by either drug's manufacturer.

That Oxford series is worth one more line. Across 750 people with UC followed for a median of nearly 13 years, 24.8% had at least one admission for acute severe colitis. Colectomy occurred in 39.8% of those with such an admission, against 3.4% of those without. The colectomy rate on a first admission was 19.9%, rising to 29.0% after two episodes and 38.2% after three (Dinesen 2010).

Print the study that disagrees

Two of them, actually.

On whether modern treatment has shortened flares. A systematic review and meta-regression of 32 studies covering 1,991 people with severe UC found a pooled short-term colectomy rate of 27% (95% CI 26 to 28%) and mortality of 1%, and concluded that the colectomy rate had not changed over the previous 30 years despite the introduction of ciclosporin (Turner 2007). Against that, a meta-analysis of 26 population-based cohorts found the overall 1-, 5- and 10-year colectomy risks in UC were 4.0%, 8.8% and 13.3%, with a significant decrease over time, and contemporary post-2000 risks of 2.8%, 7.0% and 9.6% (Tsai 2021). Both can be true: whole-population colectomy risk has fallen, while the specific subgroup admitted with acute severe colitis has been stubborn. But if you have read that new drugs have transformed severe flares, the severe-flare-specific data is more equivocal than the headline suggests.

On smoking cessation and prolonged flares. It is widely repeated, including on this site's sibling article about food and flares, that recently stopping smoking is an established trigger for worse UC. A UK nationwide study of 6,754 people with a new UC diagnosis, 878 of them smokers at diagnosis, compared persistent smokers with those who quit within two years of diagnosis. It found no significant difference in rates of steroid-requiring flares, thiopurine use, steroid dependency, hospitalisation or colectomy. Smokers and never-smokers also did not differ significantly on any of those outcomes (Blackwell 2019). That is a routinely-collected-data study, so smoking status is as good as the GP record and misclassification is likely, and an absence of a difference is not proof of no effect. But it is the largest look at the question and it does not support the folklore. Nobody should keep smoking on the strength of it.

What actually makes a flare drag on

This is the list worth going through with your IBD team when a flare is outliving its window.

Maintenance treatment that is not being taken. In a prospective cohort of 99 people with UC in remission for more than six months on maintenance mesalamine, non-adherence, defined as refilling under 80% of prescriptions, carried more than a fivefold higher risk of recurrence (hazard ratio 5.5, 95% CI 2.3 to 13). At six months, every one of the 12 people who relapsed was non-adherent (Kane 2003). The Cochrane review of oral 5-ASA for maintenance backs the underlying point: across 44 studies and 9,967 participants, 37% on 5-ASA relapsed at six to twelve months versus 55% on placebo (RR 0.68, high-certainty evidence) (Murray 2020). That review's senior author declares extensive consulting and advisory relationships across the pharmaceutical industry, including with 5-ASA manufacturers; the four other authors declare none.

An infection sitting on top of the colitis. A referral-centre study found the rate of C. difficile infection among IBD patients rose from 1.8% to 4.6% in a single year, 76% of infections were contracted as outpatients, more than half of infected patients required hospitalisation and 20% required colectomy. Notably, the usual endoscopic clue, pseudomembranes, was not seen (Issa 2007). A stool test is quick and it changes the treatment entirely.

Cytomegalovirus reactivation. A systematic review of 52 studies found 21 different definitions of CMV infection in IBD in use, which makes the prevalence figures nearly impossible to compare. Most patients with CMV infection and intestinal disease had steroid-refractory disease, and the studies came disproportionately from East Asia (Römkens 2016). It is worth knowing the possibility exists if steroids simply are not working; it is not something to conclude yourself.

NSAID painkillers. In a study of 209 people with quiescent Crohn's or UC, non-selective NSAIDs were associated with a 17 to 28% relapse rate within nine days, and relapses came with rising faecal calprotectin. Nobody relapsed early on paracetamol, on the selective COX-2 inhibitor nimesulide, or on low-dose aspirin (Takeuchi 2006). That study had roughly 20 to 32 people per arm and is now two decades old, so treat it as suggestive. If you are reaching for over-the-counter anti-inflammatories during a flare, mention it to your team.

Symptoms that are not inflammation. A meta-analysis of people with IBD in remission found about 29% of those with UC reported symptoms meeting criteria for IBS (Fairbrass 2020). If your bleeding stopped weeks ago but urgency and loose stools did not, the flare may already be over and something else may be driving the symptoms. Our post on high calprotectin with no symptoms covers the same discordance running the other way.

Mood, in both directions. A two-year prospective study of 405 people with IBD found the brain-gut relationship runs both ways: psychological distress predicted later disease activity, and disease activity predicted later anxiety and depression (Gracie 2018). That is not a claim that stress caused your flare, and the sibling post on stress, anxiety and flares unpacks how weak the causal arrow actually is. It does mean that four months into a flare, the mental load is part of what your team should be treating.

Symptoms stop before the lining heals

This is the point that changes how you read your own recovery, and it is the one most likely to make a "short" flare turn into a long one.

An Italian cohort followed 157 people with newly diagnosed UC given a first course of steroids, assessing them clinically and endoscopically at three and six months and then every six months for five years. They split them into complete responders (symptoms gone and lining healed at three months) and partial responders (symptoms gone, lining still inflamed). Over five years, hospitalisation ran at 25% in complete responders versus 48.7% in partial responders, immunosuppressive therapy at 5% versus 25.6%, and colectomy at 3.3% versus 18.0%. On multivariate analysis, lack of mucosal healing was the factor that mattered (Ardizzone 2011).

Both groups felt well at three months. Their next five years were very different.

This is why international treat-to-target guidance separates goals by timescale. STRIDE-II, developed by 89 members of the International Organization for the Study of IBD, sets symptomatic relief and normalisation of blood and stool markers as short-term targets, clinical remission and normalised CRP or calprotectin as intermediate ones, and endoscopic healing as a long-term target, alongside absence of disability and restored quality of life. Histological healing in ulcerative colitis is not a formal target but is assessed as a measure of the depth of remission (Turner 2021).

Practically, that is why your team may want a faecal calprotectin test when you feel fine. A meta-analysis of six prospective studies covering 672 people with IBD, 318 of them with UC, found calprotectin measured during remission predicted relapse with pooled sensitivity of 78% and specificity of 73%, with an area under the curve of 0.83 (Mao 2012). Useful, not decisive. Our post on how to tell if your ulcerative colitis is flaring goes into calprotectin thresholds and day-to-day variation in detail, and the PRO-2 score explainer covers what the two-item stool frequency and bleeding score does and does not capture.

How many bathroom trips a day is typical during a flare?

The survey thread asked this directly, and the answers ranged from two a day to twenty-five. That range is real lived experience and it is also useless as a benchmark, because it is a self-selected sample of people motivated enough by a bad flare to reply to a survey post.

The clinical reference points are more useful. Truelove and Witts put mild disease at under four stools a day without systemic upset and severe disease at six or more bloody stools a day with systemic features (Truelove 1955). The Simple Clinical Colitis Activity Index, still used in clinics and trials, scores daytime bowel frequency and night-time frequency as separate items alongside urgency, blood and general wellbeing (Walmsley 1998). Night-time waking counts separately precisely because it carries different information from daytime frequency.

The number that matters is not the absolute count but the change from your own baseline, and whether blood is present. Somebody whose normal is one formed stool a day going to four is in a different situation from somebody whose long-standing normal is four.

A worked example: two flares, one person, twelve weeks apart

Flare one. Bleeding appears on a Tuesday, stool frequency goes from two to five a day, no fever, no weight loss. She calls the IBD nurse on the Thursday, sends a calprotectin sample, and a topical treatment is added to her existing oral maintenance. By day ten bleeding has stopped. By week four she is back to two stools a day. She goes for a repeat calprotectin at week eight, which is normal. Total flare: about four weeks of symptoms, about eight weeks until she and her team agree it is over.

Flare two. Bleeding appears again three months later. This time she waits, because the last one settled. By week three she is going eight times a day and waking twice at night. A steroid course is started at week four. She feels dramatically better within ten days, but when the steroids taper at week twelve, symptoms return within a fortnight. Her team starts an advanced therapy, which is judged at week eight of that treatment. It does not deliver. A second advanced therapy starts, judged at its own week eight.

Same person, same disease, same colon. Flare one lasted a month. Flare two, counted from the first spot of blood to the day she was genuinely in remission, ran about nine months. Nothing about flare two was a failure of willpower or diet. Almost all of the difference is a three-week delay at the start plus the induction arithmetic of two treatment attempts.

That second pattern is exactly what the year-long forum posts are describing, and it is also why calling early matters more than any dietary decision you will make during a flare.

What you can usefully do while a flare runs

None of this replaces treatment, and none of it will shorten inflammation on its own.

• Keep a dated record of frequency, blood, urgency and night waking. Not adjectives. Numbers. "Worse" is not actionable; "from two to seven a day with blood since the 8th" gets a clinic response.
• Note when each treatment started, so you and your team can tell whether you are inside or past its induction window. This is the single most useful piece of information for deciding whether to wait or escalate.
• Report bleeding rather than absorbing it. Bleeding is the symptom that tracks inflammation most tightly, and it is the one people normalise fastest.
• Do not stop maintenance treatment when you feel better without discussing it, given the relapse figures above (Kane 2003).
• Ask about nutrition early if you are losing weight or eating very little. ESPEN's IBD guideline treats malnutrition screening and management as part of IBD care rather than an optional extra (Bischoff 2023).
• Expect fatigue to lag behind everything else. Our post on fatigue that persists into remission covers why it often outlasts the inflammation.
• Sort work before it becomes a crisis. If this flare is heading past a month, the practical guide to keeping a job with IBD covers the conversations worth having early rather than after the sick days pile up.

Tracking is also where Clairop fits: it is built for logging symptoms and meals quickly and turning them into a one-page summary to take to an appointment, which is more useful to a clinician in a short slot than a scrolling app history. It cannot tell you whether you are inflamed, and no app can.

Dangerous shortcuts that show up in the threads

Long flares make people desperate, and the forum threads behind this article contain several things worth naming.

The general principle: when a flare has run for months, the useful lever is almost always a treatment review with your IBD team, not a supplement.

Myths about how long a UC flare lasts

"The average UC flare lasts two to six weeks." There is no such published figure. That number is an induction window repackaged as a prognosis.

"If it has lasted more than a month it is not a flare." In the Danish cohort, 18% of people had disease activity every year during years three to seven (Langholz 1994). Long is not the same as impossible.

"Proctitis flares are always short." Proctitis carries lower colectomy risk over decades, but 27.1% of proctitis cases extended proximally over a mean 52 months of follow-up, and refractory disease predicted that extension (Meucci 2000).

"If I feel better the flare is over." Symptoms and mucosal healing separate routinely, and it was healing at three months, not symptoms, that predicted five-year outcomes (Ardizzone 2011).

"Steroids always work, so a flare should never last long." 16% of people with UC had no response at all to their first steroid course, and at one year only 49% had a prolonged response (Faubion 2001).

"A flare that is dragging means I ate the wrong thing." The evidence for any single food starting inflammation in a healed colon is weak, as our post on whether food can trigger a UC flare sets out in full. What has solid evidence is missed maintenance, infection and NSAIDs.

"Nothing can be done while I wait for the next drug." Stool testing for infection, checking whether your disease extent is matched to your treatment route, reviewing painkillers, and nutrition support are all live options in that window.

When to see a doctor promptly

Contact your IBD team or seek urgent care if you have any of the following, whether or not you think you are "in a flare":

• Six or more bloody stools a day, especially with fever, a racing pulse, dizziness or feeling faint. Seek urgent assessment the same day.
• Severe or worsening abdominal pain, a swollen or tender abdomen, or vomiting and being unable to keep fluids down. Seek a doctor promptly.
• Blood in your stool that is new, heavier or more frequent than your usual pattern. See a doctor promptly.
• Unexplained weight loss, or losing weight without trying during a flare.
• Night-time waking to open your bowels, which is a signal clinical scoring systems count separately for a reason (Walmsley 1998).
• Symptoms that have not improved by the end of your treatment's induction window. Ask what the plan is rather than waiting quietly.
• New symptoms outside the gut, such as painful joints, eye pain or a red eye, or mouth ulcers.
• Anaemia symptoms: breathlessness on stairs, palpitations, unusual pallor.
• Any new or unassessed symptom you have not had before. This article is written for people who already have a UC diagnosis. If you have not been assessed, do not use it to self-diagnose.

If you are struggling to get taken seriously, our guide on getting a doctor to engage with persistent gut symptoms covers the escalation routes, and the same principles apply in IBD care.

The honest bottom line

Nobody can tell you how long your flare will last, because nobody has ever measured it. What the evidence supports is narrower and more useful:

A UC flare lasts until a treatment that works for you takes hold. Treatments are judged at week 6, 8 or 10 depending on the drug, so two failed attempts is four to five months by arithmetic. About half of people are steroid free without surgery a year after their first steroid course, and about one in five people has disease active every year during the difficult stretch after diagnosis. Feeling better arrives before healing does, and the gap between them predicted five-year outcomes in the best study we have. The evidence that stopping smoking prolongs flares did not hold up in the largest population study of the question, and the evidence that new drugs have shortened severe flares specifically is more mixed than the headlines suggest.

Which means the things worth acting on are not about waiting. They are about calling early, keeping a dated record of frequency and blood, knowing which week your current treatment is meant to be judged, and asking what happens next when that week arrives and nothing has changed. That is the lever that actually moves the number you came here looking for.